Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04150497
What this trial is testing

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Cellectis S.A. 52
Large-scale testing (Phase 3)Looking for participantsNCT06193889
What this trial is testing

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Who this might be right for
Myasthenia GravisGeneralized Myasthenia Gravis
Kyverna Therapeutics 66
Testing effectiveness (Phase 2)Study completedNCT04975555
What this trial is testing

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Who this might be right for
Cytokine Release SyndromeICANSLymphoma, Non-Hodgkin+2 more
University of Alabama at Birmingham 20
Very early researchLooking for participantsNCT06318533
What this trial is testing

A Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
YANRU WANG 15
Very early researchUnknownNCT06224738
What this trial is testing

Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases

Who this might be right for
Gastric Cancer
First People's Hospital of Hangzhou 9
Testing effectiveness (Phase 2)Looking for participantsNCT06589089
What this trial is testing

Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy

Who this might be right for
Diffuse Large B Cell Lymphoma
Ruijin Hospital 18
Early research (Phase 1)Not Yet RecruitingNCT07701889
What this trial is testing

Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies

Who this might be right for
Hematologic Diseases
Roswell Park Cancer Institute 21
Very early researchLooking for participantsNCT05060796
What this trial is testing

Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Second Affiliated Hospital of Guangzhou Medical University 11
Early research (Phase 1)Active Not RecruitingNCT03070327
What this trial is testing

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 20
Early research (Phase 1)UnknownNCT05698303
What this trial is testing

Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd. 12
Early research (Phase 1)Looking for participantsNCT07587125
What this trial is testing

Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS) Primary ProgressiveMultiple SclerosisMultiple Sclerosis (MS) Secondary Progressive+1 more
Xijing Hospital 9
Testing effectiveness (Phase 2)UnknownNCT04778579
What this trial is testing

Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy

Who this might be right for
Acute Lymphoid Leukemia
Sara V. Latorre 50
Early research (Phase 1)Looking for participantsNCT04545762
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Refractory Non-Hodgkin LymphomaBurkitt LymphomaMantle Cell Lymphoma+7 more
C. Babis Andreadis 36
Early research (Phase 1)Looking for participantsNCT07162038
What this trial is testing

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Who this might be right for
Hematologic MalignanciesHematologic Neoplasms
National Cancer Institute (NCI) 155
Early research (Phase 1)Looking for participantsNCT07295847
What this trial is testing

AZD0120 in Autoimmune Diseases

Who this might be right for
Systemic SclerosisIdiopathic Inflammatory MyopathiesRheumatoid Arthritis
AstraZeneca 27
Early research (Phase 1)WithdrawnNCT04556266
What this trial is testing

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Who this might be right for
LeukemiaLymphomaLymphoma, B-Cell
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)UnknownNCT03767725
What this trial is testing

Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Shenzhen Second People's Hospital 10
Early research (Phase 1)WithdrawnNCT07093086
What this trial is testing

Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
B-cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Testing effectiveness (Phase 2)Active Not RecruitingNCT06665256
What this trial is testing

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Who this might be right for
Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals 21
Early research (Phase 1)WithdrawnNCT04094766
What this trial is testing

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Who this might be right for
Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
Next Page